Get the Stockscreener App
106.57
1.57%
1.65
Biontech Se Adr stock is traded at $106.57, with a volume of 1.32M.
It is up +1.57% in the last 24 hours and up +12.77% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$104.92
Open:
$106.01
24h Volume:
1.32M
Relative Volume:
1.10
Market Cap:
$26.08B
Revenue:
$2.97B
Net Income/Loss:
$-812.83M
P/E Ratio:
-31.38
EPS:
-3.3962
Net Cash Flow:
$-1.24B
1W Performance:
-1.77%
1M Performance:
+12.77%
6M Performance:
-11.47%
1Y Performance:
+11.01%
1-Day Range:
$105.12
$107.70
1-Week Range:
$104.00
$110.00
52-Week Range:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
106.57 | 26.08B | 2.97B | -812.83M | -1.24B | -3.3962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail
Is BioNTech Stock A Buy On Major $11 Billion Cancer-Drug Deal? - Barchart.com
Bristol Myers Collaborates With BNTX for Oncology Candidate - sharewise
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - Yahoo Finance
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Bristol-Myers and BioNTech: Oncology Collaboration Further Solidifies BNT327's Potential - Morningstar
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine - Yahoo Finance
BioNTech’s SWOT analysis: oncology pipeline and mRNA tech drive stock potential - Investing.com
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards For COVID-19 Shots - Barchart.com
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots - Zacks Investment Research
BioNTech to invest up to £1bn in UK R&D expansion - Sharecast.com
Market news - investments.halifax.co.uk
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
BioNTech SE ADR (NASDAQ: BNTX): Getting A Free Pass? - Stocksregister
Balance Sheet Breakdown: BioNTech SE ADR (BNTX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Why BioNTech Stock Got Trounced On Tuesday - Barchart.com
BioNTech SE Reports Q1 2025 Financial Results - TipRanks
BioNTech’s Earnings Call: Oncology Progress Amid Financial Challenges - TipRanks
BioNTech Earnings: Guidance Reiterated, Oncology Development Continues to Advance - Morningstar
BioNTech SE ADR [NASDAQ: BNTX] Sees Increase in Stock Value - knoxdaily.com
HRL Shares Experience Surge in Value - knoxdaily.com
Nordson Corp [NDSN] stock for 268,620 USD was sold by Lovass Stephen - knoxdaily.com
Hanesbrands Inc [HBI] Records 200-Day SMA of $6.81 - knoxdaily.com
Ratio Review: Analyzing Regency Centers Corporation (REG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Metrics Exploration: Understanding MARA Holdings Inc (MARA) Through Ratios - DWinneX
Financial Fitness Check: Examining BioNTech SE ADR (BNTX)’s Key Ratios - DWinneX
The growth track for BioNTech SE ADR (BNTX) has changed recently - Sete News
Financial Health Report: Arthur J. Gallagher & Co (AJG)’s Ratios Tell a Tale - DWinneX
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales - sharewise
A year in review: BioNTech SE ADR (BNTX)’s performance in the last year - uspostnews.com
BioNTech SE ADR (NASDAQ: BNTX) Could Make Significant Gains? - Marketing Sentinel
Investors Could Make -86.23% On NOV Inc (NYSE: NOV) Stock - Marketing Sentinel
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
Is Murphy Oil Corp (NYSE: MUR) Stock Set To Rise More? - Marketing Sentinel
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
BioNTech SE ADR (BNTX) Stock: A Year of Market Fluctuations - investchronicle.com
Faraday Future Intelligent Electric Inc (FFAI) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Community Health Systems, Inc Inc. (CYH) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Checking in on BioNTech SE ADR (BNTX) after recent insiders movement - knoxdaily.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Yahoo Finance
BioNTech SE ADR [BNTX] Shares Jump Approximately 32.28% Over the Year - knoxdaily.com
Today’s watch list includes BioNTech SE ADR (NASDAQ:BNTX) stock - uspostnews.com
AMKOR Technology Inc [AMKR] Records 200-Day SMA of $26.99 - knoxdaily.com
Fluence Energy Inc [FLNC] Officer makes an insider purchase of 78,258 shares worth 0.29 million. - knoxdaily.com
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):